Education
About Us
Working with TipRanks
Follow Us
Argenx Se (DE:1AEA)
FRANKFURT:1AEA
1AEA Stock Chart & Stats
Day’s Range― - ―
52-Week Range€322.00 - €660.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$33.75B
Enterprise ValueN/A
Total Cash (Recent Filing)$321.37M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)48.3
Beta-0.12
Next Earnings
May 08, 2025EPS Estimate
2.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.81
Shares Outstanding60,760,956
10 Day Avg. Volume1
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)86.46
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€689.22Price Target Upside20.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
---
Bulls Say, Bears Say
Bulls Say
EarningsARGX reported preliminary Q4 global Vyvgart/Vyvgart Hytrulo product net sales of $737M, beating consensus estimates by 14%.
Market ExpansionThe PFS approval is anticipated to expand Vyvgart's use to new patients, contributing to its growth.
Bears Say
Product DevelopmentARGX is discontinuing development of Vyvgart in BP based on results from the Ph.2 BALLAD study.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
19.91% Mutual Funds
8.09% Other Institutional Investors
70.61% Public Companies and Individual Investors
1AEA FAQ
What was Argenx Se’s price range in the past 12 months?
Argenx Se lowest stock price was €322.00 and its highest was €660.00 in the past 12 months.
What is Argenx Se’s market cap?
Argenx Se’s market cap is $33.75B.
When is Argenx Se’s upcoming earnings report date?
Argenx Se’s upcoming earnings report date is May 08, 2025 which is in 59 days.
How were Argenx Se’s earnings last quarter?
Argenx Se released its earnings results on Oct 31, 2024. The company reported €1.327 earnings per share for the quarter, beating the consensus estimate of €0.14 by €1.186.
Is Argenx Se overvalued?
According to Wall Street analysts Argenx Se’s price is currently Undervalued.
Does Argenx Se pay dividends?
Argenx Se does not currently pay dividends.
What is Argenx Se’s EPS estimate?
Argenx Se’s EPS estimate is 2.21.
How many shares outstanding does Argenx Se have?
Argenx Se has 60,760,956 shares outstanding.
What happened to Argenx Se’s price movement after its last earnings report?
Argenx Se reported an EPS of €1.327 in its last earnings report, beating expectations of €0.14. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Argenx Se?
Currently, no hedge funds are holding shares in DE:1AEA
---
Argenx Se Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€689.22 (20.92% Upside)
€689.22 (20.92% Upside)
Blogger Sentiment
Bullish
DE:1AEA Sentiment 80%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
52.87%
12-Months-Change
Fundamentals
Return on Equity
-5.75%
Trailing 12-Months
Asset Growth
50.18%
Trailing 12-Months
Company Description
Argenx Se
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.
---
1AEA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements in clinical milestones, financial growth, and pipeline expansion, indicating strong momentum. However, there were challenges with exchange losses and an operating loss despite revenue growth. Overall, the positive aspects and future outlook outweigh the negatives.Read More>---
1AEA Stock 12 Month Forecast
Average Price Target
€689.22
▲(20.92% Upside)
Technical Analysis
Alnylam Pharma
―
Biogen
―
Regeneron
―
Vertex Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering 1AEA
1 Year
1 Year Success Rate
21/24 ratings generated profit
1 Year Average Return
+45.70%
reiterated a buy rating 12 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +45.70% per trade.
---